IMR Press / FBS / Volume 13 / Issue 2 / DOI: 10.52586/S563
Open Access Case Report
Metformin-associated lactic acidosis and acute kidney injury in the era of COVID-19
Show Less
1 Department of Nephrology, General Hospital of Nikaia-Piraeus, 18454 Athens, Greece
Front. Biosci. (Schol Ed) 2021 , 13(2), 202–207; https://doi.org/10.52586/S563
Submitted: 12 September 2021 | Revised: 26 October 2021 | Accepted: 8 November 2021 | Published: 3 December 2021
Copyright: © 2021 The Author(s). Published by BRI.
This is an open access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
Abstract

COVID-19, provoked by SARS-CoV-2, constitutes a global health issue with high rates of mortality. The presence of diabetes mellitus is associated with severe coronavirus COVID-19 as it is related to increased death rates in patients admitted to the intensive care unit. Acute kidney injury is a frequent complication among patients hospitalized for COVID-19 and is met with high morbidity and mortality. Here, we present a case of a diabetic patient with acute kidney injury, metformin-associated lactic acidosis, and COVID-19. Lactic acidosis is a relatively rare but noteworthy complication of metformin use. However, the combination of those life-threatening situations could prove fatal for the patients despite optimal medical care.

Keywords
Metformin-associated lactic acidosis
Acute kidney injury
COVID-19
Metformin
Figures
Fig. 1.
Share
Back to top